NIH Reporter #75N91019D00024-0-759102500020-1

NIH solicitation for project management and research services to produce Usher III retinal organoids from patient cells.

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), seeks project management and research services for producing Usher III retinal organoids from patient cells. - Government Buyer: - National Cancer Institute (NCI), NIH - Located in Frederick, Maryland - Scope of Work: - Project management for retinal organoid research - Teleconference management - Protocol development - Reporting on research progress - Research Focus: - Production of retinal organoids from patient cells - Measurement of drug candidate effects for Usher III syndrome - Estimated Contract Value: - Approximately $794,843 - NAICS Codes: - 541712: Research and Development in the Physical, Engineering, and Life Sciences - 541690: Other Scientific and Technical Consulting Services - No specific OEMs, vendors, or product line items are mentioned - No unique license or classification requirements noted

Description

This project involves producing retinal organoids from patient cells to evaluate the effect of a drug candidate related to Usher III syndrome. The scope includes project management for retinal organoid research, teleconference management, protocol development, and reporting. The project duration is from September 15, 2025, to March 15, 2028, with an estimated award amount of approximately $794,843 for fiscal year 2025. The work is to be performed in Frederick, MD, by LEIDOS BIOMEDICAL RESEARCH, INC.

View original listing